ProShare Advisors
APLT

ProShare Advisors’s Applied Therapeutics APLT Stock Holding History

ProShare Advisors’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,446
Closed -$12.9K – 2082
2025
Q1 		$12.9K Sell
26,446
-6,142
-19% -$3.62K ﹤0.01% 2063
2024
Q4 		$27.9K Buy
32,588
+14,420
+79% +$90.4K ﹤0.01% 2239
2024
Q3 		$154K Buy
+18,168
New +$107K ﹤0.01% 1793

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ProShare Advisors's APLT Position: Q2 2025 in Review

ProShare Advisors sold out of Applied Therapeutics (APLT) in Q2 2025, closing a stake of 26,446 shares — an estimated $12.9K sold.

ProShare Advisors first reported a position in APLT in Q3 2024 and held it in 3 quarters. The position peaked at $154K in Q3 2024. 75 funds tracked by Wall St. Rank hold APLT as of Q2 2025.

  • ProShare Advisors reported no remaining Applied Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 26,446 Applied Therapeutics shares in Q2 2025, an estimated $12.9K.
  • ProShare Advisors first reported a position in Applied Therapeutics in Q3 2024 and held it in 3 quarters.
  • ProShare Advisors's Applied Therapeutics position peaked at $154K in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.